Tag:

Daiichi Sankyo

Latest Headlines

Latest Headlines

Japan's Daiichi Sankyo revamps operations, management, ahead of olmesartan expiry

Daiichi Sankyo has revamped management roles and will cut reporting lines on April 1, ahead of the looming loss of its patent protection of flagship hypertension drug olmesartan (Benicar) in key markets this year to shore up its group structure.

Japan biotech AnGes MG transfers local Collatagene marketing rights to Mitsubishi Tanabe

AnGes MG has formed a new partnership with Mitsubishi Tanabe Pharma Corporation for the marketing of investigational gene therapy Collategene (beperminogene perplasmid) in Japan, ending ties with Daiichi Sankyo.

Daiichi's new clot-fighter Savaysa can't make up for $2.6B Benicar patent loss: analysts

Daiichi Sankyo's got a big revenue hurdle coming up, with top treatment Benicar set to lose patent protection next year. A black-box warning on its new drug Savaysa isn't helping matters. So analysts are wondering what the company can do to plug the forthcoming sales holes.

Ranbaxy sale to Sun Pharmaceuticals appears on track

The U.S. Federal Trade Commission said the $4 billion deal for Japan's Daiichi Sankyo to sell its troubled Ranbaxy Laboratories unit to Sun Pharmaceutical looks to be OK as long as Ranbaxy divests its generic minocycline antibacterial to Torrent Pharmaceuticals.

Ranbaxy-Sun U.S. approval hinges on selling antibacterial drug as FTC notes reach of Indian generic giant

Ranbaxy Laboratories may soon be selling its generic minocycline antibacterial drug to Torrent Pharmaceuticals as a condition for U.S. approval for its merger with Sun Pharmaceuticals.

Daiichi Sankyo to pay $39M to settle DOJ claims it paid kickbacks to docs

Japanese drugmaker Daiichi Sankyo will pay the $39 million to the state and federal health programs, and a whislteblower, to settle claims it paid doctors kickbacks to prescribe some of its drugs, Reuters reports.

Daiichi's Savaysa goes up against next-gen anticoagulant trio in heated market race

What's long been a three-horse race just gained a fourth horse with the FDA's green light for Daiichi Sankyo's clot-fighter Savaysa. With the FDA's Thursday blessing, the drug will now face down a new-age anticoagulant trifecta that's been duking it out in the marketplace for a while now.

Daiichi Sankyo wins FDA nod for a new a-fib drug

The FDA signed off on Daiichi Sankyo's clot-preventing edoxaban, giving the Japanese drugmaker the green light to compete in a crowded market for next-generation anticoagulants.

Daiichi Sankyo's new a-fib drug heads toward FDA approval and a crowded market

A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.

Daiichi Sankyo gains some in-house FDA support for a-fib drug edoxaban

Daiichi Sankyo's campaign to win approval for its atrial fibrillation drug edoxaban gained some support from regulators at the FDA who were clearly won over by the efficacy data in the NDA. But the internal review of the drug also includes recommendations for limiting its use to patients with abnormal kidney function. And they include a few cautionary notes on the competing drugs that have already made it to the market.